Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at the Fondazione Prada in Milan
- “Effect of nasal anti-CD3 (foralumab) in animal model of Progressive Multiple Sclerosis (MS)” poster exhibit
- “Effect of nasal anti-CD3 (foralumab) in healthy subjects” poster exhibit
- “Effect of nasal anti-CD3 (foralumab) in patient with Progressive MS” poster exhibit
Howard L. Weiner, M.D. of Brigham and Women’s Hospital (BWH) and Tiziana Scientific Advisory BoardChairman, interviewed first patient to receive internasal foralumab for Secondary Progressive MS (SPMS)
“Preserving the Brain” is a scientific forum and exhibit on neurodegenerative diseases as part of the “Human Brains” neuroscience project held in Fondazione Prada in
At the “Translation of Scientific Discovery to Patient Care” workshop,
“I am absolutely thrilled that foralumab was highlighted at the Fondazione Prada’s “Preserving the Brain” international forum,” commented
Dr. Weiner’s patient interview (presented at the conference on 27th
About Fondazione Prada and the “Preserving the Brain” Exhibit
The exhibition will be held from 16 September to 10 October 2022 in the Podium, the space at the center of Fondazione Prada's Milan venue. Conceived by the New York studio 2x4, the exhibition design will be divided into different sections supervised by the research centers, and a common central area that will encourage dialogue and exchanges between the thirteen institutes. Each section will examine a specific research process on neurodegenerative diseases employing video presentations, technological objects and instruments, scientific documents, and visual materials.
Throughout the opening of the exhibition, the 13 institutions participating in the project will give a series of online workshops that will be available to the public at humanbrains.fondazioneprada.org. Each meeting will enable the assessment of a specific aspect in the search for new treatments for neurodegenerative diseases.
The pivotal moment of "Preserving the Brain" will be the scientific conference held on 6 and 7 October 2022, at Fondazione Prada's Cinema in Milan. The speakers will explore the subject of neurodegenerative diseases from different perspectives, such as genetic implications and molecular mechanisms, clinical trials and possible drug treatments. The conference is addressed to researchers and universities involved in the project and representatives of prominent institutions in the health sector. The sessions will also be streamed and visible to all on the online platform: humanbrains.fondazioneprada.org.
Foralumab (formerly NI-0401), the only entirely human anti-CD3 mAb, has shown reduced release of cytokines after IV administration in healthy volunteers and in patients with Crohn's disease. In a humanized mouse model (NOD/SCID IL2γc-/-), it was shown that while targeting the T-cell receptor, orally administered foralumab modulates immune responses of the T-cells and enhances regulatory T-cells (Tregs), thereby providing therapeutic benefit in treating inflammatory and autoimmune diseases without the occurrence of potential adverse events usually associated with parenteral mAb therapy. Once a day treatment for 10 consecutive days with intranasal foralumab was both well tolerated and produced clinical responses in COVID-19 patients. Based on these studies, the intranasal and oral administration of Foralumab offers the potential to become a well-tolerated immunotherapy for autoimmune and inflammatory diseases by the induction of Tregs.
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For further inquiries:
+44 (0) 207 495 2379
Source: Tiziana Life Sciences Ltd.